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Abstract
Background: The autoantibody profile of seropositive rheumatoid arthritis (RA) is very diverse and consists of
various isotypes and antibodies to multiple post-translational modifications. It is yet unknown whether this varying
breadth of the autoantibody profile is associated with treatment outcomes. Therefore, we investigated whether the
composition of the autoantibody profile in RA, as a marker of the underlying immunopathology, influences initial and
long-term treatment outcomes.
Methods: In serum from 399 seropositive patients with RA in the IMPROVED study, drawn at baseline and at the
moment of drug tapering, we measured IgG, IgM, and IgA isotypes for anti-cyclic citrullinated peptide-2 and anti‐
carbamylated protein antibodies, IgM and IgA rheumatoid factor, and reactivity against four citrullinated and two
acetylated peptides (anti-modified protein antibodies (AMPAs)). We investigated the effect of the breadth of the
autoantibody profile on (1) change in disease activity score (DAS)44 between 0 and 4 months, (2) initial drug-free
remission (DFR, drug-free DAS44 < 1.6) achieved between 1 and 2 years of follow up, and (3) long-term sustained
DFR until last follow up.
Results: Patients with a broad autoantibody profile at baseline had a significantly better early treatment response:
ΔDAS 0–4 months of 1–2, 3–4, and 5–6 vs 7–8 isotypes, -1.5 (p < 0.001), -1.7 (p = 0.03), and -1.8 (p = 0.04) vs -2.2. Similar
results were observed for AMPA number. However, patients with a broad baseline autoantibody profile achieved less
initial DFR. For long-term sustained DFR there was no longer an association with the breadth of the autoantibody
response. When assessing autoantibodies at the moment of tapering, similar trends were observed.
Conclusions: A broad baseline autoantibody profile is associated with a better early treatment response. The breadth
of the baseline autoantibody profile, reflecting a break in tolerance against several different autoantigens and extensive
isotype switching, may indicate a more active humoral autoimmunity, which could make the underlying disease
processes initially more suppressible by medication. The lack of association with long-term sustained DFR suggests that
the relevance of the baseline autoantibody profile diminishes over time.
Trial registration: ISRCTN11916566. Registered on 7 November 2006. EudraCT, 2006- 06186-16. Registered on
16 July 2007.
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Background
Patients with rheumatoid arthritis (RA), a chronic auto-
immune disease primarily affecting the joints, harbour
autoantibodies recognizing several post-translationally
modified peptides. The most well-characterised of these
are anti-citrullinated peptide 2 (anti-CCP2) antibodies and
rheumatoid factor (RF) that are present in approximately
60% of patients. Anti-CCP2 and RF-positive patients have
a worse long-term prognosis and are less likely to achieve
drug-free remission (DFR) [1–5]. Whether they also differ
in early treatment response is controversial [5–8].
However, considering only these two autoantibodies
may be oversimplifying a complex picture. Novel RA-
associated autoantibody systems such as anti-carbamylated
protein (anti-CarP) [9, 10] and anti-acetylated protein anti-
bodies [11] continue to be identified. Moreover, the auto-
antibody profile is very diverse, with antibodies targeting
variable numbers of different peptides with the same
post-translational modification, and with marked he-
terogeneity in isotype usage [12–14]. This diversity in
the breadth of the autoantibody profile most likely
reflects the break of tolerance to multiple autoantigens
and the maturity of the humoral autoimmune response
[15–17].
It is currently unknown to what extent the breadth of
the autoantibody profile influences treatment outcomes.
In RA, early initiation of disease-modifying anti-
rheumatic drugs (DMARDs) and treat-to-target strat-
egies have improved clinical remission rates [18, 19] and
in some patients tapering and withdrawal of DMARDs
can be attempted, but not all patients successfully be-
come symptom-free or drug-free. There is a growing
need to understand the mechanisms that set apart pa-
tients that do achieve early clinical remission or long-
term sustained DFR (the closest approximation of dis-
ease curative available) [3, 20, 21].
Since autoantibodies are linked to both RA patho-
physiology and treatment outcomes, they offer a unique
perspective to shed light on the pathophysiological
mechanisms underlying RA chronicity. Given the vary-
ing composition of the RA autoantibody profile (with its
diversity in autoantigen recognition and extensive iso-
type switching), it appears plausible that the breadth of
this profile could be associated with treatment out-
comes. No studies to date have investigated the effect of
composition of the baseline autoantibody profile on early
response to conventional DMARD therapy or long-term
DFR. Furthermore, it is also unclear whether the breadth
of the profile present at baseline or at the moment of
drug-tapering (or both) is more indicative the ability of a
patient to reach and maintain DFR. To fill these niches
in knowledge, we investigated whether outcomes such as
early treatment response to DMARDs and DFR are asso-
ciated with the breadth of the autoantibody profile at




The Induction therapy with Methotrexate and Prednis-
one in Rheumatoid Or Very Early arthritic Disease (IM-
PROVED) study is a multicentre, randomized controlled
trial that enrolled 610 patients with early (< 2 years) un-
treated RA or undifferentiated arthritis. It was aimed at
change in the disease activity score-remission (DAS44 <
1.6), and for those achieving remission, aimed at drug-
free remission (DFR), with treatment adjusted every
4 months according to whether treatment targets had
been reached. Initial treatment comprised methotrexate
(MTX) and high-dose prednisone, followed by either ta-
pering of medication or randomization to one of two
treatment arms: MTX, prednisone, hydroxychloroquine,
and sulphasalazine combination (multi-DMARD arm) or
MTX and adalimumab combination as described previ-
ously [2]. According to the protocol, patients tapered and
discontinued methotrexate at 8 months if they achieved
early remission, allowing them to become drug-free and
remain so until the DAS increased to > 1.6.
Patient selection and outcomes
All 479 patients fulfilling the 2010 American College of
Rheumatology (ACR)/European League Against Rheuma-
tism (EULAR) RA criteria were selected. Of these patients,
those seropositive at baseline by routine clinical testing for
anti-CCP2 IgG or RF IgM, or by our in-house assay for
anti‐CarP IgG [10], were selected (n = 395; see Fig. 1 for
detailed selection algorithm). If patients were fully sero-
negative at baseline, we measured anti-CCP2 IgG, RF
IgM, and anti-CarP IgG in serum collected after 1 year of
follow up to include any patients that seroconverted to
positive, yielding 399 seropositive patients, of whom
356 had baseline, untreated serum available and 209
had 8-month treated serum available for further sero-
logical measurements as described subsequently [2].
Main outcomes we investigated were initial DAS
change from baseline to 4 months (ΔDAS 0–4 months)
and DFR. DAS change from baseline to 4 months oc-
curred under treatment with MTX and high-dose pred-
nisone. DFR was defined as the ability to discontinue
medication and remain in remission for (at least) 1 year
after achieving DAS44 < 1.6. We differentiated between
initial DFR and long-term sustained DFR. Initial DFR
was defined as DFR between 1 and 2 years of the study,
which due to the protocol could only be achieved by pa-
tients that were in early DAS remission at 4 months
after tapering prednisone and MTX. Long-term sus-
tained DFR was defined as DFR of at least 1 year dur-
ation until the last follow up in all patients (including
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those who were randomized to the multi-DMARD or
adalimumab treatment arm), which is the closest ap-
proximation of disease cure currently available for RA.
Due to the protocol design, the group of patients that
could achieve initial DFR was smaller than (i.e. a sub-
group of) all patients who could achieve long-term sus-
tained DFR.
Serological measurements
Enzyme-linked immunosorbent assay (ELISA) was used
essentially as described previously to measure anti-CCP2
IgG, IgM, and IgA [22], RF IgM and IgA [12], and anti-
CarP IgG, IgM, and IgA [10, 23] in baseline serum from
untreated patients. We also conducted fine-specificity
ELISA for IgG directed against four citrullinated peptides:
citrullinated-vimentin 59-74, citrullinated-fibrinogen β 36-
52 and α 27-43, and citrullinated-enolase 5-20 [24]. Last,
ELISA for anti-acetylated lysine and anti-acetylated orni-
thine IgG (Orgentec Diagnostika GmbH, Germany) was
performed as previously described [11].
Absorbance was converted to arbitrary units per milli-
litre (aU/mL) using a standard curve of pooled, serially
diluted highly positive patient serum. Samples were con-
sidered positive if they fell above the cutoff of the mean
aU/mL value plus two standard deviations in serum
samples from 76 healthy controls from the Leiden area,
run in tandem with the samples for each ELISA. Because
antibodies may be aspecifically directed to the unmodi-
fied variant of the peptide/protein of interest, we applied
a specificity criterion to each ELISA. For anti-CCP2 IgA
Fig. 1 Extended patient selection algorithm. ACR, American College of Rheumatology; EULAR, European League Against Rheumatism; RA, rheumatoid
arthritis; anti-CCP2, anti-citrullinated protein 2; RF, rheumatoid factor; anti-CarP, anti-carbamylated protein antibodies; AMPA, anti-modified
protein antibodies; Cit, citrullinated
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and IgM, the difference between the citrullinated and
unmodified optical density (OD) had to be more than
0.1; for anti-CarP and anti-acetylated peptide ELISAs,
the difference (aU/mL) between the modified and un-
modified signal had to be above the cut-off. Since previ-
ous experiments revealed minimal aspecific signals for
the citrullinated fine-specificity ELISA, no specificity cri-
terion was applied.
The technical success rate of the ELISA was at least
96% (Fig. 1). There was good agreement in positivity be-
tween the original baseline measurement performed rou-
tinely for anti-CCP-antibodies and RF at inclusion and
the in-house baseline re-measurement (Additional file 1:
Figure S1).The first and second in-house measurement
of anti-CarP IgG showed fair agreement (Additional file 1:
Figure S1). Positivity for the various isotypes measured
largely overlapped (Additional file 1: Figure S2).
Statistical analysis
We constructed categories reflecting the breadth of the
antibody response that consisted of the sum of positive
antibody tests. First, the number of isotypes present; both
in total (anti-CCP2 IgG, IgM, IgA; RF IgM, IgA; anti-CarP
IgG, IgM, IgA; range 1-8) and per family (anti-CCP2 and
anti-CarP range 1-3; RF range 1–2). Second, the number
of IgG anti-modified peptide responses, both in total
(anti-CCP2 IgG, anti-CarP IgG, anti-citrullinated-vimentin
59-74 IgG, anti-citrullinated-fibrinogen β 36-52 IgG, and
α 27-43 IgG, anti-citrullinated-enolase 5-20 IgG, anti-
acetylated-lysine IgG, anti-acetylated-ornithine IgG; range
1–8) and per modification (citrullinated peptides range 1–
4; acetylated peptides range 1–2). Differences between cat-
egories were calculated using analysis of variance
(ANOVA) for continuous outcomes (DAS and ΔDAS 0–4
months), adjusted for age, gender, and smoking (ever/
never), and baseline body mass index and Health Assess-
ment Questionnaire (HAQ) score, which were independ-
ent predictors of early remission in the IMPROVED study
[5]. Binary logistic regression was used for categorical out-
comes, adjusted as above, with the analyses of initial DFR
additionally adjusted for baseline DAS and the analyses of
long-term sustained DFR additionally adjusted for baseline
DAS and treatment arm. Holmes-Bonferroni methods
were used to correct the alpha level for multiple testing,
assuming the same number of hypotheses as pairwise
comparisons made. All reported p values are derived from
the analysis models following correction; only p values
that remained significant after correction for multiple test-
ing are reported in the figures.
Results
Antibody positivity at baseline and 8 months
At baseline in the full cohort, 68% (323/472) of patients
were anti-CCP2 IgG positive, 70% (330/469) were RF
IgM positive, and 39% (162/416) were anti-CarP IgG
positive. Within the patients that were positive for at
least one of these autoantibodies at baseline or at 1 year
(n = 399), we (re)measured anti-CCP2, RF, and anti-CarP
isotypes and anti-citrullinated and anti-acetylated pep-
tide antibodies in baseline serum and in 8-month serum.
Since we selected patients based on baseline seropositiv-
ity of anti-CCP2 IgG, RF IgM, or anti-CarP IgG, the high
rates of positivity for these antibodies at baseline and
8 months are to be expected (Table 1). The lower rates
of antibody positivity at 8 months compared to baseline
are largely due to seroconversion from positive to nega-
tive in this time period.
Initial change in DAS
We first analysed the association between the patients’
baseline autoantibody profiles and initial treatment
response. As shown in Fig. 2a, seropositive patients
(defined by the presence of anti-CCP2 IgG and/or RF
IgM and/or anti-CarP IgG in the original baseline





RA (2010 criteria), n (%) 356 (100%) -
Female sex, n (%) 243 (68%) -
Age, mean years (SD) 51.2 (13.2) -
Symptom duration (weeks), median (IQR) 18 (9-35)a -
Ever smokers 165 (47%)a -
DAS, mean ± SD 3.3 (0.9) -
Anti-CCP2 IgG, n (%) 292 (82%) 168 (80%)
Anti-CCP2 IgM, n (%) 146 (41%) 62 (30%)
Anti-CCP2 IgA, n (%) 150 (42%) 58 (28%)
RF IgM, n (%) 267 (75%) 121 (58%)
RF IgA, n (%) 212 (60%)a 84 (40%)a
Anti-CarP IgG, n (%) 175 (49%) 64 (31%)
Anti-CarP IgM, n (%) 141 (40%) 35 (17%)
Anti-CarP IgA, n (%) 109 (32%)a 23 (11%)
Anti-cetyl-Lysine IgG, n (%) 130 (37%) 67 (32%)
Anti-Acetyl-Ornithine IgG, n (%) 252 (71%) 132 (63%)
Anti-Cit-Vim IgG, n (%) 208 (58%) 100 (48%)
Anti-Cit-Fib α IgG, n (%) 101 (28%) 29 (14%)
Anti-Cit-Fib β IgG, n (%) 213 (60%) 105 (50%)
Anti-Cit-Eno IgG, n (%) 115 (32%) 58 (28%)
Number of isotypes, median (IQR) 4 (2–6)a 3 (1–4)a
Number of AMPAs, median (IQR) 4 (2–-6) 4 (2–5)
Vim vimentin, Fib fibrinogen, Eno enolase, IQR interquartile range, Lys lysine,
Orn ornithine, SD standard deviation
aSome missing values. See Fig. 1 for number of data available on individual
antibody measurements. Available data for symptom duration and smoking,
n = 355; for anti-CarP IgA, n = 344 at baseline; for number of isotypes n = 343
at baseline; n = 208 at 8 months
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measurement) had a lower DAS at baseline than triple-
negative patients. This was most likely due to the ACR/
EULAR2010 RA criteria selection we used; seropositive
patients require fewer other clinical items to fulfil the
criteria and thus have a lower DAS at baseline than sero-
negative patients. Notably, despite these differences in
Fig. 2 Disease activity score (DAS) (mean +/- 95% confidence intervals) over 4 months of treatment and mean initial change in DAS from baseline to
4 months (ΔDAS 0–4 months), separated by baseline serological status and breadth of autoantibody response. a, b DAS over time and ΔDAS
0–4 months separated by baseline autoantibody seropositivity based on anti-citrullinated protein 2 (anti-CCP2) IgG, rheumatoid factor (RF)
IgM, or anti-carbamylated protein (anti-CarP) IgG positivity. Based on availability of antibody data, the total number of patients included in a and b is
472. c, d Within baseline seropositive patients, DAS over time and ΔDAS 0–4 months separated by the total number of isotypes present (anti-CCP2
IgG, IgM, IgA; RF IgM, IgA; and anti-CarP IgG, IgM, IgA). Due to the technical success rate of isotype measurements, and some seropositive patients
testing negative upon re-measurement (see Additional file 1: Figure S1), the total number of patients included in c and d is 325. e, f Within patients
seropositive at baseline, DAS over time and ΔDAS 0–4 months separated by the total number of anti-modified peptide antibodies (AMPAs) present
(anti-CCP2 IgG, anti-CarP IgG, anti-citrullinated-vimentin 59-74 IgG, anti-citrullinated-fibrinogen β 36-52 IgG and α 27-43 IgG, anti-citrullinated-enolase
5-20 IgG, anti-acetylated-lysine IgG, and anti-acetylated-ornithine IgG). Thirty-eight patients were RF IgM positive but had no AMPAs (not shown).
Due to the technical success rate of isotype measurements and some anti-CCP2 IgG and anti-CarP IgG positive patients testing negative upon
re-measurement (see Additional file 1: Figure S1), the total number of patients included in e and f is 318. g Within baseline seropositive patients,
ΔDAS 0–4 months separated by the number of isotypes present per antibody family and for the number of antibodies present to citrullinated or
acetylated peptides. Reported p values are adjusted for multiple testing using Holmes-Bonferroni methods. ns, not significant (p ≥ 0.05); *p < 0.05;
**p < 0.01, ***p < 0.001. Anti-cit. pept. Abs, anti-citrullinated peptide antibodies; Anti-acetyl. pept. Abs, anti-acetylated peptide antibodies
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absolute DAS, the initial change in DAS from baseline
to 4 months was equal between seropositive and seronega-
tive patients (Fig. 2b and Additional file 1: Figure S3A),
also after correction for relevant covariates.
Strikingly, within the seropositive patients, initial
DAS response in patients with many isotypes was more
pronounced than in those with few isotypes (ΔDAS 0–4
months of 7–8 isotypes vs 1–2, 3–4, and 5–6 isotypes,
respectively: -2.2 vs -1.5 (p < 0.001), -1.7 (p = 0.003),
and -1.8 (p = 0.001)) (Fig. 2c, d and Additional file 1:
Figure S3B). This pattern remained when analysing the
number of isotypes present separately for each antibody
family: those with more isotypes had better initial DAS
response than those with fewer isotypes, and were sta-
tistically significant (after correction for multiple test-
ing) for the RF and anti-CarP families (Fig. 2g).
There was the same dose-dependent association be-
tween breadth of the autoantibody profile and DAS de-
cline when analysing the overall number of AMPAs
present. Initial DAS response in seropositive patients
with many AMPAs was better than in those with few
AMPAs, although this was not always statistically sig-
nificant after correction for multiple testing: ΔDAS 0–4
months of 7–8 AMPAs vs 1–2, 3–4, and 5–6 AMPAs,
respectively: -2.1 vs -1.7 (p = 0.016), -1.5 (p < 0.001),
and -1.9 (p =0.22) (Fig. 2e, f and Additional file 1:
Figure S3C). This pattern was also present when ana-
lysing the number of antibodies present per post-
translational modification, and was significant for
citrullinated peptides: ΔDAS 0–4 months of 3–4 vs 1–2
citrullinated peptides was -2.0 vs -1.6 (p = 0.01) (Fig. 2g).
No single isotype or antibody was disproportionally as-
sociated with a better initial DAS response (Additional
file 1: Figure S4A).
Initial successful drug discontinuation
To investigate whether the autoantibody profile at baseline
or at the moment of tapering was also relevant for more
long-term treatment outcomes, we next examined
whether the autoantibody response is associated with abil-
ity to discontinue medication and remain in remission for
one year after reaching early remission (initial DFR), inde-
pendently of factors also associated with this outcome (see
“Statistical analysis”). In line with previous findings [2], pa-
tients with RA who were positive for anti-CCP2 IgG and/
or RF IgM were less likely than their negative counterparts
to reach initial DFR, although this difference was not sig-
nificant: 17% of anti-CCP2 IgG positive versus 20% of
negative patients (p = 0.14) and 16% of RF IgM positive
versus 19% of negative patients (p = 0.43). Anti-CarP IgG
positive patients were also less likely to reach initial DFR
than negative patients (11% vs 22%; p = 0.03). Since we se-
lected patients on ACR/EULAR2010 RA criteria, thereby
enriching for seropositivity, the differences between anti-
CCP2 IgG, RF IgM, and anti-CarP positive and nega-
tive patients found here were less pronounced than
previously reported in the entire IMPROVED study
population because in the current study patients
negative for one of these antibodies were by definition
positive for another [2].
Interestingly, while a broad baseline autoantibody re-
sponse was favourable for initial DAS response, it was
unfavourable for the chance of achieving initial DFR
(Fig. 3). Within patients seropositive for anti-CCP2 IgG,
RF IgM, or anti-CarP IgG at baseline, there was a non-
significant trend indicating that patients with more iso-
types achieve less initial DFR (1–2, 3–4, and 5–6 isotypes
vs 7–8 isotypes, respectively: 21% (p = 0.07), 20% (p =
0.13), and 20% (p = 0.10) vs 3%) (Fig. 3a). Patients with
more AMPAs also achieved significantly less initial DFR
(1–2 AMPAs vs 3–4, 5–6, and 7–8 AMPAs, respectively:
37% vs 13% (p = 0.004), 14% (p = 0.007), and 11% (p =
0.005) (Fig. 3b).
This trend remained when examining the number of
isotypes present separately for each antibody family and
the number of antibodies present against citrullinated/
acetylated peptides (Fig. 3c). The presence of an anti-
CCP2 IgM and/or IgA isotype within patients positive
for anti-CCP2 IgG did not decrease the chance of initial
DFR, nor did the presence of RF IgA in patients posi-
tive for conventional RF IgM (data not shown). Pres-
ence of a specific isotype or antibody did not confer
increased or decreased chance of reaching initial DFR
(Additional file 1: Figure S4B).
We investigated whether the autoantibody profile at
the moment of tapering had a similar association with
initial DFR as the baseline profile. Patients received ta-
pered methotrexate at 8 months if they achieved early
remission, allowing them to reach initial DFR between
12 months and 2 years. Seropositive patients with more
isotypes at 8 months (i.e. the moment of tapering)
tended to achieve less initial DFR than those with few
isotypes, but this effect was not as clear as observed in
relation to the baseline profile (Fig. 4a). Patients with
more AMPAs at 8 months achieved slightly less initial
DFR (1–2 AMPAs vs 3–4, 5–6, and 7–8 AMPAs, re-
spectively: 38% vs 24% (p = 0.025), 10% (p = 0.004), and
13% (p = 0.023) (Fig. 4b)), but only the comparison of 1–
2 AMPAs with 5–6 AMPAs remained significant after
correction for multiple testing. When examining the
antibody families separately, there was no clear pattern
indicating that more isotypes or reactivity against citrul-
linated/acetylated peptides was associated with less ini-
tial DFR (Fig. 4c).
Long-term sustained DFR
Finally, we wished to determine whether the baseline
autoantibody profile was associated with the most
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favourable long-term outcome of long-term sustained
DFR. Fifty-seven percent of patients that had initial DFR
also achieved long-term sustained DFR, defined as at
least 1 year of DFR lasting until the last follow up, an
outcome approximating disease cure. For patients that
were not in early remission at 4 months and therefore
could not achieve initial DFR, it was still possible to
taper medication at a later stage and reach long-term
sustained DFR. In the full RA cohort, baseline anti-
CCP2 IgG positive patients reached this outcome signifi-
cantly less often than their negative counterparts (10%
vs 26% (p < 0.001)); RF IgM and anti-CarP IgG positive
patients followed a similar trend (14% vs 19% (p = 0.05).
In contrast to the previous results on initial DFR
(broad baseline autoantibody response: decreased chance
of initial DFR), there was no difference in rates of long-
term sustained DFR between seropositive patients with
many isotypes versus few isotypes, or between patients
with many AMPAs versus few AMPAs (Fig. 5a, b). Fur-
thermore, when separately assessing the number of iso-
types in a family and the number of antibodies present
against citrullinated/acetylated peptides, there were also
no differences in long-term sustained DFR rates (Fig. 5c).
Only anti-CarP isotypes showed a trend that was no lon-
ger present after correction for multiple testing: one iso-
type versus two isotypes and three isotypes, respectively:
20% vs 12% (p = 0.49) and 5% (p = 0.02). The presence of
an anti-CCP2 IgM and/or IgA isotype within patients
positive for anti-CCP2 IgG did not decrease the chance
of long-term sustained DFR, nor did the presence of a
RF IgA in patients positive for conventional RF IgM
(data not shown). Last, positivity to a specific isotype or
Fig. 3 Association between baseline autoantibody profile and initial drug-free remission (DFR) in patients seropositive for anti-citrullinated protein 2
(anti-CCP2) IgG, rheumatoid factor (RF) IgM, or anti-carbamylated protein (anti-CarP) IgG at baseline that had serum available for re-measurement
(n = 155). Pairwise comparisons between each group were not significant after multiple testing (see text). a Percentage of patients with the
specified number of isotypes present reaching initial DFR. The composite number of isotypes consists of the positivity count for anti-CCP2 IgG,
IgM, IgA; RF IgM, IgA; and anti-CarP IgG, IgM, IgA. Due to the technical success rate of isotype measurements, and some seropositive patients
testing negative upon re-measurement (see Additional file 1: Figure S1), the total number of patients included in a is 140. b Percentage of
patients with the specified number of anti-modified protein antibodies (AMPAs) present reaching initial DFR. The composite number of AMPAs
consists of the positivity count for anti-CCP2 IgG, anti-CarP IgG, anti-citrullinated-vimentin 59-74 IgG, anti-citrullinated-fibrinogen β 36-52 IgG,
α 27-43 IgG, anti-citrullinated-enolase 5-20 IgG, anti-acetylated-lysine IgG, and anti-acetylated-ornithine IgG. Eleven patients were RF IgM positive but
had no AMPA antibodies (not shown). c Percentage of patients with the specified number of antibodies present reaching initial DFR. Anti-cit. pept.
Abs, anti-citrullinated peptide antibodies; Anti-acetyl. pept. Abs, anti-acetylated peptide antibodies. Reported p values are adjusted for multiple testing
using Holmes-Bonferroni methods. ns, not significant (p≥ 0.05); *p < 0.05; **p < 0.01, ***p < 0.001
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antibody did not confer increased or decreased chances
of reaching long-term sustained DFR (Additional file 1:
Figure S4C).
It is conceivable that patients who achieved early re-
mission had different chances of reaching long-term
sustained DFR than the full IMPROVED population ex-
amined here, and that results would have been different
for the patients who achieved early remission. To inves-
tigate this, we performed sensitivity analysis of the
association between baseline antibody profile and long-
term sustained DFR in only the patients who achieved
early remission. The results were the same in this group
as in the whole cohort (Additional file 1: Figure S5).
Discussion
The present study explored the link between the
humoral autoimmune response and clinical outcomes by
investigating whether the breadth of patients with RA
with a seropositive autoantibody profile was associated
with early and late treatment outcomes. We were able
to show, for the first time, that the number of auto-
antibodies at baseline was independently and dose-
dependently associated with a greater decrease in the
DAS after 4 months of conventional DMARD therapy.
Conversely, a broad autoantibody profile at baseline
was associated with a smaller chance of achieving DFR
at early stages of attempted drug tapering (initial DFR),
but not later in the treatment regimen, where long-
term sustained DFR was unrelated to the breadth of the
autoimmune response. We also found that reassessing
the autoantibody profile at the moment of drug-
tapering does not provide additional information about
the chance of successfully discontinuing medication to
that provided by the baseline profile.
We examined three primary outcomes: initial DAS re-
sponse, initial DFR, and long-term sustained DFR. Little
Fig. 4 Association between 8-month autoantibody profile and initial drug-free remission (DFR) in patients seropositive for anti-citrullinated protein
2 (anti-CCP2) IgG, rheumatoid factor (RF) IgM, or anti-carbamylated protein (anti-CarP) IgG at baseline, who had serum available for re-measurement at
8 months (n = 103). Pairwise comparisons between each group were not significant after multiple testing (see text). a Percentage of patients with the
specified number of isotypes present reaching initial DFR. The composite number of isotypes consists of the positivity count for anti-CCP2 IgG, IgM,
IgA; RF IgM, IgA; and anti-CarP IgG, IgM, IgA. Due to some seropositive patients testing negative upon re-measurement or seroconverting to negative
by 8 months, the total number of patients with any isotypes present was 92. b Percentage of patients with the specified number of anti-modified
protein antibodies (AMPAs) present reaching initial DFR. The composite number of AMPAs consists of the positivity count for anti-CCP2 IgG,
anti-CarP IgG, anti-citrullinated-vimentin 59-74 IgG, anti-citrullinated-fibrinogen β 36-52 IgG and α 27-43 IgG, anti-citrullinated-enolase 5-20
IgG, anti-acetylated-lysine IgG, and anti-acetylated-ornithine IgG. Thirteen patients were RF IgM positive but had no AMPA antibodies or had
seroconverted to negative by 8 months (not shown). c Percentage of patients with the specified number of antibodies present reaching initial
DFR. Anti-cit. pept. Abs, anti-citrullinated peptide antibodies; Anti-acetyl. pept. Abs, anti-acetylated peptide antibodies. Reported p values are
adjusted for multiple testing using Holmes-Bonferroni methods. ns, not significant (p ≥ 0.05); *p < 0.05; **p < 0.01, ***p < 0.001
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is known about the relationship between initial DAS re-
sponse and autoantibody profile in RA. Although some
studies suggest that seropositive patients with RA with a
high level or large number of autoantibodies have a bet-
ter response to B cell-depleting therapy [25, 26], this is
the first study that shows that the magnitude of sero-
positivity is favourable for DAS response under conven-
tional synthetic DMARD therapy as well.
As for the second outcome, initial DFR, Figueiredo et
al. recently showed that patients with a broad pattern of
AMPA response are at high risk of disease relapse in the
first year after DMARD tapering [27]. Although the
trend we found for initial DFR was significant for the
number of AMPAs, our findings do not fully support
Figueiredo’s observation that a broad autoantibody pro-
file is unfavourable for DFR because we did not identify
a dose-dependent effect. The most likely reason is that
we used a different, more stringent outcome (i.e. main-
taining DFR for a full year) and that we only measured
seropositive patients. As such, we had no patients with
zero antibodies at baseline, whereas Figueiredo et al. did
have such patients, and the contrast with patients with
more antibodies was less striking. We also investigated
whether the autoantibody profile at the moment of drug
tapering (8 months in the IMPROVED study) instead of
at baseline determines the chance of successfully discon-
tinuing medication without disease flare. We found that
a broad profile at this moment was not associated with
initial DFR. These findings are relevant as they indicate
that characterising the autoantibody profile at the mo-
ment of tapering does not yield additional information
over baseline.
Last, we found that the ability to achieve the third out-
come, long-term sustained DFR (at least 1 year of DFR
until the last follow up), was independent of the breadth
of the baseline autoantibody profile. Instead, baseline
seropositivity for anti-CCP2 IgG was the only relevant
factor associated with inability to achieve long-term
Fig. 5 Association of baseline autoantibody profile with long-term sustained drug-free remission (DFR) in patients seropositive for anti-citrullinated
protein 2 (anti-CCP2) IgG, rheumatoid factor (RF) IgM, or anti-carbamylated protein (anti-CarP) IgG at baseline (n = 336). Pairwise comparisons between
each group were not significant after multiple testing (see text). a Percentage of patients with the specified number of isotypes present reaching long-
term sustained DFR. The composite number of isotypes consists of the positivity count for anti-CCP2 IgG, IgM, IgA; RF IgM, IgA; and anti-CarP IgG, IgM,
IgA. Due to the technical success rate of isotype measurements, and some seropositive patients testing negative upon re-measurement (see Additional
file 1: Figure S1), the total number of patients included in a is 309. b Percentage of patients with the specified number of anti-modified protein
antibodies (AMPAs) present reaching long-term sustained DFR. The composite number of AMPAs consists of the positivity count for anti-CCP2
IgG, anti-CarP IgG, anti-citrullinated-vimentin 59-74 IgG, anti-citrullinated-fibrinogen β 36-52 IgG and α 27-43 IgG, anti-citrullinated-enolase 5-20
IgG, anti-acetylated-lysine IgG, and anti-acetylated-ornithine IgG. Thirty-six patients were RF IgM positive but had no AMPA antibodies (not shown).
c Percentage of patients with the specified number of antibodies present reaching long-term sustained DFR. Anti-cit. pept. Abs, anti-citrullinated
peptide antibodies; Anti-acetyl. pept. Abs, anti-acetylated peptide antibodies
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sustained DFR, which is similar to other publications de-
scribing presence of anti-CCP2 IgG and RF IgM as a
poor prognosticator of long-term drug-free remission
[1–5].
Together, these results indicate that the breadth of the
autoantibody response in seropositive patients is relevant
for early treatment response, somewhat relevant for early
attempted drug tapering, but irrelevant for later out-
comes (Fig. 6). The presence of multiple antibodies at
baseline may indicate an active, ongoing autoimmune re-
sponse against various post-translationally modified pro-
teins and antigenic targets present in RA, and reflects
extensive isotype switching. It is likely that such active
immune responses are more susceptible to suppression
by methotrexate and prednisone in the initial stages, as
evidenced by the stronger early DAS improvement.
The association between the breadth of the autoanti-
body profile and disease outcomes diminished in magni-
tude as the outcome investigated became further
removed from baseline. This implies that the breadth of
baseline autoantibody profile is mostly relevant for
short-term outcomes, and has implications for the
mechanisms underlying disease chronicity. It has re-
cently been shown that memory B cells expressing anti-
citrullinated peptide antibodies (ACPA) persist in the
circulation [28, 29], despite conventional DMARD use
and remission of synovial disease [30]. These data indi-
cate the persistent presence of a population of auto-
reactive B cells that is not affected by therapy. Perhaps
the best indicator of this long-lived autoimmunity that
accounts for the inability to become drug-free in the
long run is presence of this persistent B cell population
(the presence of which can be best measured by the
anti-CCP IgG test), rather than the recognition of mul-
tiple modified antigens or the presence of multiple auto-
antibody isotypes at baseline. This would explain why
anti-CCP2 IgG positivity (firmly established in the
literature) but not more antibodies (as in this study) is a
poor prognostic factor for DFR.
Another explanation why the breadth of the autoanti-
body response is only important for early outcomes (i.e.
DAS and initial DFR) could be that the autoantibody
profile changes during treatment preceding late
attempted drug tapering. Indeed, this seemed to be the
case as some seroconversion happened between baseline
and 8 months. However, considering that the profile at
the moment of tapering did not yield more information
than the baseline profile for the outcome initial DFR, it
does not appear very likely that characterising the profile
at even later time points would have yielded more infor-
mation on later outcomes (i.e. long-term sustained
DFR). Furthermore, changes in antibody profile were not
the focus of the current investigation.
This study has a few limitations. We chose not to cor-
rect for baseline DAS in the case of ΔDAS 0–4 months
because doing so may lead to biased results when the
explicit outcome of interest is change from baseline [31].
We also performed in-depth serotyping only in patients
positive for anti-CCP2 IgG, RF IgM, and/or anti-CarP
IgG, so it is possible that we missed some patients who
harboured a certain isotype or fine-specificity. However,
it has been shown that the occurrence of IgA and IgM
anti-CCP2 and responses to citrullinated and acetylated
peptides are largely confined to the anti-CCP2 IgG posi-
tive subset. No data are available for anti-CarP isotypes,
but it seems likely that our broad definition of seroposi-
tivity would have captured most anti-CarP isotypes as
well, especially since anti-CarP is known to co-occur
with anti-CCP2 IgG or RF IgM [32].
Strengths of the current study include that, to the best
of our knowledge, it is the broadest autoantibody profile
investigation in RA to date (eight isotypes and six fine
specificities within four autoantibody systems), in a co-
hort with an exceptionally long follow up. Furthermore,
Fig. 6 Summary of results. Colours of the antibodies indicate diversity in antigenic targets, and structures indicate diversity in the isotype usage.
A broad baseline profile (left) is favourable for early response, but has no association with long-term outcomes like drug-free remission, as compared
to a less broad baseline profile (right). The association with the breadth of the baseline profile diminishes with time
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it is the first study that investigates the relationship be-
tween the number of autoantibodies and early response
to conventional DMARD therapy. The associations we
identified cannot be explained by differences in treat-
ment or in demographic characteristics, as we adjusted
all analyses for these. Last, we characterized the antibody
profile both at baseline and at the moment of attempted
drug-tapering, something that, to our knowledge, has
not been investigated thus far.
Conclusions
This large study shows that seropositive patients with
RA with a broader autoantibody profile at baseline ini-
tially respond better to treatment and have a slightly
worse chance of achieving DFR at early stages, but that
the magnitude of seropositivity does not affect the ability
to taper off medication and remain in remission later in
disease. In early stages of disease, a broad autoantibody
profile may reflect active humoral immunity, which
could make the underlying disease processes initially
more suppressible by medication. The importance of the
baseline autoantibody profile for treatment outcomes di-
minishes over time.
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